4D Molecular Therapeutics, Inc.FDMTNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-138.37M
↓ 124% below average
Average (7y)
$-61.78M
Historical baseline
Range
High:$7.66M
Low:$-138.37M
CAGR
NaN%
Modest growth trend
| Period | Value | Change |
|---|---|---|
| 2024 | $-138.37M | -76.1% |
| 2023 | $-78.56M | +20.0% |
| 2022 | $-98.22M | -25.5% |
| 2021 | $-78.24M | -50.7% |
| 2020 | $-51.91M | -30.1% |
| 2019 | $-39.91M | -139.5% |
| 2018 | $-16.67M | -317.5% |
| 2017 | $7.66M | - |